COVID-19 is a contagious disease that is caused by the newly discovered virus called Coronavirus. This disease is mainly associated with an inflammation that is dysregulated. The effects of treating COVID -19 using a combination of baricitinib plus remdesivir have not been discovered, yet the impacts are remarkable. Remdesivir is a drug designed for the delivery of inter-cellular as well as for the modification of adenine nucleoside. Baricitinib on the other hand is a Janus kinase inhibitor. A combination of baricitinib and remdesivir is more effective than the use of remdesivir alone as the two drugs effectively reduces the recovery time as well as increasing the rate of improvement involved in the clinical status among the patients suffering from COVID-19. This is because the two drugs reduce their period of recovery from eighteen days to ten days.
Effectiveness of Baricitinib Plus Remdesivir on COVID-19 Patients
In current research conducted to find the effectiveness of Baricitinib Plus Remdesivir on patients suffering from COVID-19 who had been hospitalized, randomized, double-blind, and placebo-controlled trials were used to evaluate the two drugs. All the patients in this study received remdesivir and either placebo or baricitinib. One thousand thirty-three patients took part in the trial. Baricitinib Plus Remdesivir was used on 515 of the study participants, while 518 acted as the control group. This study showed that a combination of the two drugs was influential in reducing the patients’ recovery time from eight to seven days. This study also revealed that the Baricitinib Plus Remdesivir is essential for patients with COVID-19; thus, this combination requires more investigations and studies.
Studies have shown that the two drugs work effectively when used together. The application of Baricitinib Plus Remdesivir is more effective than the use of remdesivir alone. This is because it appropriately helps reduce the recovery period and raise the level of improvement of patients’ clinical statuses suffering from COVID-19. This is more effective on patients receiving a high oxygen flow and those under noninvasive ventilation (Kalil et al., 2020). Baricitinib is a prospective therapeutic against severe COVID-19 since it inhibits the intercellular signal ways of the cytokines that are always eminent in the extreme conditions of COVID-19 and inhibiting multiple interleukins such as interleukin-2, 6, and 10. It is also useful as it helps in improving the counts of lymphocytes in the patients having COVID-19.
The faster recovery rate among patients who receive Baricitinib Plus Remdesivir shows that the combination of the two drugs affects lowering the errors encountered in the administration of medicines in the hospitals and lowering various hospital-associated infections (Titanji et al., 2020). Additionally, faster recovery rates reduce the healthcare system’s weight, thus potentially raising the volume that is very vital during the flow of cases.
In conclusion, studies have ascertained how effective Baricitinib Plus Remdesivir is in the treatment of COVID-19 patients. A combination of the two drugs is compelling as they help reduce the median time of recovery among the patients hospitalized for COVID-19 from a span of eight to seven days. Additionally, the two drugs’ application is practical on patients with a higher flow of oxygen since the drugs shorten their recovery time from a span of eighteen days to ten days.